EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that CEO Nancy Lurker will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:30 AM ET. The event will be streamed live and an archived replay will be available on the company's website for 90 days. EyePoint is focused on innovative ophthalmic products addressing unmet medical needs, with two commercial products: DEXYCU and YUTIQ. Their pipeline includes EYP-1901, a VEGF inhibitor aimed at treating various serious eye disorders. For more information, visit www.eyepointpharma.com.
- None.
- None.
WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:30 AM ET.
A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company's website at www.eyepoint.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intravitreal drug delivery including EYP-1901, a VEGF inhibitor, targeting wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.
Contacts
Investors:
Argot Partners
Sam Martin or Joe Rayne
212-600-1902
eyepoint@argotpartners.com
Media:
Thomas Gibson
201-476-0322
tom@tomgibsoncommunications.com
FAQ
When will EyePoint Pharmaceuticals present at the Jefferies Virtual Healthcare Conference?
How can I access the EyePoint Pharmaceuticals presentation?
What are the commercial products offered by EyePoint Pharmaceuticals?
What is EYP-1901 developed by EyePoint Pharmaceuticals?
Where is EyePoint Pharmaceuticals headquartered?
